# Royalty Pharma plc (RPRX) FY2025 Q1 P&L / Income Statement

- Company: Royalty Pharma plc (RPRX)
- Period: 2025-01-01 to 2025-03-31
- Filing: Q1 FY2025 10-Q, filed 2025-05-08, accession number 0001802768-25-000027
- Page: https://plicit.ai/financials/rprx/fy2025-q1-income-statement
- Chart image: https://plicit.ai/charts/rprx-fy2025-q1-income-statement-sankey.png

## Chart details: Revenue by Product and Service

Income statement for 2025-01-01 through 2025-03-31. View: Product and service. Revenue uses this breakdown; costs and expenses retain the consolidated categories.

- **Total income and other revenues**: 568,247,000 US dollars
- **Total operating expense, net**: 34,065,000 US dollars
- **Operating income/(loss)**: 534,182,000 US dollars
- **Total other expense/(income), net**: negative 100,749,000 US dollars
- **Consolidated net income/(loss) before tax**: 433,433,000 US dollars
- **Income tax expense**: 0 US dollars
- **Consolidated net income/(loss)**: 433,433,000 US dollars
- **Income from financial royalty assets**: 539,490,000 US dollars
- **Other royalty income and revenues**: 28,757,000 US dollars
- **Research and development funding expense**: 50,500,000 US dollars
- **Provision for changes in expected cash flows from financial royalty assets**: negative 127,140,000 US dollars
- **General and administrative expenses**: 110,705,000 US dollars

### Chart connections

- Revenue minus operating expenses equals operating income.
- Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.
- Of which attributable to Royalty Pharma plc: $238.35 M; to noncontrolling interests: $195.08 M.